Long-term treatment with BRAF inhibitors such as vemurafenib triggers the selection of resistant melanoma cells that, as a consequence of a mitochondrial respiration phenotype, exhibit increased ROS production and increased redox response [62]. The gene discussed is BRAF; the disease is melanoma.